VRDN

$29.0615.53%3.905

Nachbörslich: 29.72+0.66 +2.29%

Viridian Therapeutics Inc (VRDN)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$25.15

Offen:

$28.27

24-Stunden-Volumen:

11,165,399

Relatives Volumen:

3.64

Marktkapitalisierung:

$3.29B

Einnahmen:

$70.92M

Nettoeinkommen (Verlust:

-$342.21M

KGV:

EPS:

-$3.76

Netto-Cashflow:

-$304.30M

1W Leistung:

+19.72%

1M Leistung:

+49.77%

6M Leistung:

+106.65%

1Y Leistung:

+28.85%

1-Tages-Spanne:

$25.07$29.74

1-Wochen-Bereich:

$23.97$29.74

52-Wochen-Spanne:

$13.18$34.29

Viridian Therapeutics Inc Aktie (VRDN) Unternehmensprofil

Firmenname

Viridian Therapeutics Inc

Sektor

Healthcare

Branche

Biotechnology

Telefon

617.272.4600

Adresse

221 CRESCENT STREET, WALTHAM, USA

Mitarbeiter

252

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

VRDN-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Viridian Therapeutics Inc Aktie (VRDN) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-06-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-12-10	Bestätigt	Wedbush	Outperform
2025-12-03	Eingeleitet	William Blair	Outperform
2025-11-24	Eingeleitet	Truist	Buy
2025-08-25	Resumed	Jefferies	Buy
2024-12-19	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-11-25	Eingeleitet	TD Cowen	Buy
2024-09-11	Bestätigt	Needham	Buy
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-06-06	Eingeleitet	Goldman	Buy
2024-05-09	Herabstufung	B. Riley Securities	Buy → Neutral
2024-05-09	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2023-06-14	Eingeleitet	BTIG Research	Buy
2023-06-14	Resumed	Credit Suisse	Outperform
2023-05-30	Eingeleitet	RBC Capital Mkts	Outperform
2023-04-17	Eingeleitet	Wells Fargo	Overweight
2023-03-30	Eingeleitet	Stifel	Buy
2022-12-19	Eingeleitet	Cowen	Outperform
2022-12-19	Eingeleitet	Needham	Buy
2022-12-16	Eingeleitet	Credit Suisse	Outperform
2022-12-01	Eingeleitet	H.C. Wainwright	Buy
2022-06-23	Eingeleitet	B. Riley Securities	Buy
2021-11-18	Eingeleitet	SVB Leerink	Outperform
2021-10-12	Eingeleitet	Evercore ISI	Outperform
2021-01-25	Eingeleitet	Ladenburg Thalmann	Buy

Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	70.85	0.30	0.31	1.77	2.96
Operating expenses USD (M)	434.24	299.34	254.76	136.08	82.69
Operating income USD (M)	-363.40	-299.04	-254.45	-134.30	-79.73
Income before tax USD (M)	-	-	0.31	1.77	2.96
Income tax expense USD (M)	0.00	-	-	-	-
Net income USD (M)	-342.60	-269.95	-237.73	-129.87	-79.41
Basic EPS USD/shares	-	-	-5.31	-4.05	-6.66
Diluted EPS USD/shares	-	-	-5.31	-4.05	-6.66
Basic weighted shares shares (M)	-	-	44.76	32.09	11.92
Diluted weighted shares shares (M)	-	-	44.76	32.09	11.92
Selling, general and administrative USD (M)	95.32	-	-	-	-

Viridian Therapeutics Inc-Aktie (VRDN) Insiderhandel

Tousignant JenniferAug 19 '26
Chief Legal Officer
Transaktion
Option Exercise
Kosten
$14.41
#Aktien
10,000
Wert ($)
144,100
#Aktien Gesamt
10,000
Tousignant JenniferAug 19 '26
Chief Legal Officer
Transaktion
Sale
Kosten
$24.50
#Aktien
14,212
Wert ($)
348,194
#Aktien Gesamt
0
Tousignant JenniferAug 19 '26
Officer
Transaktion
Proposed Sale
Kosten
$24.50
#Aktien
14,212
Wert ($)
348,194
#Aktien Gesamt
0
Tripuraneni RadhikaAug 14 '26
Chief Medical Officer
Transaktion
Option Exercise
Kosten
$13.21
#Aktien
40,000
Wert ($)
528,400
#Aktien Gesamt
40,000
Fairmount Funds Management LLCMay 11 '26
Director
Transaktion
Buy
Kosten
$17.00
#Aktien
1,176,470
Wert ($)
19,999,990
#Aktien Gesamt
5,090,928
Beetham Thomas W.Mar 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$30.19
#Aktien
3,048
Wert ($)
92,004
#Aktien Gesamt
0
Tousignant JenniferMar 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$30.19
#Aktien
1,675
Wert ($)
50,560
#Aktien Gesamt
0
Harmon SethMar 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$30.19
#Aktien
2,031
Wert ($)
61,306
#Aktien Gesamt
0
Mahoney Stephen F.Mar 04 '26
Officer
Transaktion
Proposed Sale
Kosten
$30.19
#Aktien
7,408
Wert ($)
223,610
#Aktien Gesamt
0
Tousignant JenniferDec 31 '25
Chief Legal Officer
Transaktion
Sale
Kosten
$31.16
#Aktien
2,272
Wert ($)
70,796
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Tousignant Jennifer	Chief Legal Officer	Aug 19 '26	Option Exercise	$14.41	10,000	144,100	10,000
Tousignant Jennifer	Chief Legal Officer	Aug 19 '26	Sale	$24.50	14,212	348,194	0
Tousignant Jennifer	Officer	Aug 19 '26	Proposed Sale	$24.50	14,212	348,194	0
Tripuraneni Radhika	Chief Medical Officer	Aug 14 '26	Option Exercise	$13.21	40,000	528,400	40,000
Fairmount Funds Management LLC	Director	May 11 '26	Buy	$17.00	1,176,470	19,999,990	5,090,928
Beetham Thomas W.	Officer	Mar 04 '26	Proposed Sale	$30.19	3,048	92,004	0
Tousignant Jennifer	Officer	Mar 04 '26	Proposed Sale	$30.19	1,675	50,560	0
Harmon Seth	Officer	Mar 04 '26	Proposed Sale	$30.19	2,031	61,306	0
Mahoney Stephen F.	Officer	Mar 04 '26	Proposed Sale	$30.19	7,408	223,610	0
Tousignant Jennifer	Chief Legal Officer	Dec 31 '25	Sale	$31.16	2,272	70,796	0

Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten

Nov 03, 2026

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates - Zacks Investment Research

Nov 03, 2026

Sep 22, 2026

Viridian Therapeutics (NasdaqCM:VRDN) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 22, 2026

Sep 08, 2026

Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada

Sep 08, 2026

Sep 03, 2026

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga

Sep 03, 2026

Sep 02, 2026

Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - theglobeandmail.com

Sep 02, 2026

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance

Sep 02, 2026

Wells Fargo healthcare conference sets Sept. 8 chat with Viridian - Stock Titan

Sep 02, 2026

Aug 31, 2026